Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase II Trial of TisaGenlecleucel (Kymriah®) in Elderly Patients With First-Relapsed or Primary Refractory Agressive B-cell Non-Hodgkin Lymphoma (TIGER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04161118
Recruitment Status : Not yet recruiting
First Posted : November 13, 2019
Last Update Posted : November 13, 2019
Sponsor:
Collaborator:
Novartis
Information provided by (Responsible Party):
Prof. Dr. Peter Borchmann, University of Cologne

Brief Summary:
A phase II trial of TisaGenlecleucel (Kymriah®) in Elderly Patients with First-Relapsed or Primary Refractory Agressive B-cell Non-Hodgkin Lymphoma

Condition or disease Intervention/treatment Phase
Non Hodgkin Lymphoma Drug: Kymriah Phase 2

Detailed Description:
This is a single-arm, prospective, multicenter phase-II trial for elderly patients with aNHL failing 1st-line treatment with immunochemotherapy containing rituximab and anthracycline, who are not eligible for either autologous or allogeneic stem cell transplantation, defined as age > 65 years, or > 60 years old with HCT-CI score >2. This trial evaluates the CMR rate 12 weeks after tisagenlecleucel (Kymriah®) infusion, the incidence and severity of adverse events, progression-free survival, and overall survival after one and two years after tisagenlecleucel (Kymriah®).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Trial of TisaGenlecleucel (Kymriah®) in Elderly Patients With First-Relapsed or Primary Refractory Agressive B-cell Non-Hodgkin Lymphoma
Estimated Study Start Date : August 2020
Estimated Primary Completion Date : August 2023
Estimated Study Completion Date : February 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: Tisagenlecleucel (Kymriah®)
All patients will receive a single target dose of 0.6 to 6.0 × 108 of autologous tisagenlecleucel (Kymriah®) transduced T-cells with a viability of at least 70% administered via IV infusion after optional bridging with chemo- or immunotherapy and lymphodepleting (LD) chemotherapy with cyclophosphamide and fludarabine.
Drug: Kymriah
IV Infusion




Primary Outcome Measures :
  1. The primary objective is to estimate efficacy of treatment with tisagenlecleucel (Kymriah®) in elderly patients with r/r aNHL: Complete metabolic response (CMR) rate [ Time Frame: 12 weeks after tisagenlecleucel (Kymriah®) infusion ]
    Complete metabolic response (CMR) rate 12 weeks after tisagenlecleucel (Kymriah®) infusion


Secondary Outcome Measures :
  1. Incidence and severity of adverse events (AEs) [ Time Frame: From study start to study end (44 months) ]
    Incidence and severity of adverse events (AEs)

  2. Progression-free survival (PFS) rates at 1 and 2 year(s) [ Time Frame: Up to two years from study start ]
    Progression-free survival (PFS) rates at 1 and 2 year(s)

  3. Overall survival (OS) rates at 1 and 2 year(s) [ Time Frame: Up to two years from study start ]
    Overall survival (OS) rates at 1 and 2 year(s)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   60 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Written, signed and dated informed consent must be obtained prior to participation in the study
  2. Patients with first relapse of aggressive B-cell Non-Hodgkin Lymphoma (aNHL) within 365 days after rituximab- and anthracycline-containing first-line immunochemotherapy or aNHL refractory to first-line therapy (not achieving a CR or PR), who are ineligible for either autologous or allogeneic stem cell transplantation, defined by age > 65 years, or > 60 years with a HCT-CI score > 2 (https://qxmd.com/calculate/calculator_108/hematopoietic-cell-transplantation-specific-comorbidity-index-hct-ci) and not older than 80 years.
  3. Histologically confirmed (by local histopathological assessment) aNHL at relapse or progression due to refractory disease after front line therapy. aNHL is defined by the following list of subtypes:

    1. DLBCL, NOS (GCB, ABC, centroblastic, immunoblastic, anaplastic)
    2. FL grade 3B
    3. T-cell-rich/histiocyte-rich large B-cell lymphoma (T/HRBCL)
    4. DLBCL associated with chronic inflammation
    5. Intravascular large B-cell lymphoma
    6. ALK+ large B-cell lymphoma
    7. B-cell lymphoma, unclassifiable, (with features intermediate between DLBCL and classical HL)
    8. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements
    9. High-grade B-cell lymphoma, NOS
    10. HHV8+ DLBCL, NOS
    11. DLBCL transformed from follicular lymphoma
    12. DLBCL transformed from marginal zone lymphoma
    13. DLBCL, leg type
  4. Measurable disease:

    1. Nodal lesions >15 mm in the long axis, regardless of the length of the short axis, and/or
    2. Extranodal lesions (outside lymph node or nodal mass, but including liver and spleen) >10 mm in long AND short axis
  5. ECOG performance status 0-2
  6. Adequate organ function:

    a. Kidney function defined as: i. Serum creatinine estimated glomerular filtration rate GFR ≥ 30mL/min b. Hepatic function defined as: i. ALT and AST ≤ 5 × ULN, except for aNHL-related functional impairment. ii. Bilirubin ≤2.0 mg/dl except for patients with Gilbert syndrome, who may be included if their total bilirubin is ≤3.0 × ULN and direct bilirubin ≤1.5 × ULN OR for aNHL-related functional impairment c. Adequate bone marrow function (regardless of transfusion) defined as: i. WBC ≥2500/µL ii. Absolute neutrophil count (ANC) >1000/µL iii. Platelets ≥50,000/µL iv. Hemoglobin >8.0 g/dl d. Minimum level of pulmonary function defined as: i. No or mild dyspnea (≤ Grade 1) ii. pulse oxygenation ≥ 91% on room air

  7. Life expectancy of more than six months
  8. Women have to be in menopausal or post-menopausal status or confirmed as not having potential on childbearing
  9. Male participants with female partners of childbearing potential are eligible to participate if they agree to contraceptive methods as described in the study protocol

Exclusion Criteria:

  1. Patients with Richter's transformation, Burkitt lymphoma, or primary CNS lymphoma (PCNSL)
  2. Prior treatment with anti-CD19 therapy, adoptive T-cell therapy, or any prior gene therapy product
  3. Treatment with any lymphoma-directed second-line anticancer therapy prior to enrollment with the exception of intermittent steroid therapy. After enrollment, bridging therapy is permitted for disease control.
  4. Patients with active CNS involvement are excluded, except if the CNS involvement has been effectively treated (i.e. patient is asymptomatic) and local treatment was >4 weeks before enrollment
  5. Prior allogeneic bone marrow transplantation (HSCT)
  6. Active hepatitis B, hepatitis C, or hepatitis E infection
  7. HIV-positive patients
  8. Uncontrolled acute life threatening bacterial, viral or fungal infection (e.g. blood culture positive ≤ 72 hours prior to infusion)
  9. Any of the following cardiovascular conditions:

    1. Unstable angina, myocardial infarction, coronary artery bypass graft (CABG), or stroke within 6 months prior to screening,
    2. LVEF <45% as determined by ECHO at screening except for aNHL-related functional impairment,
    3. NYHA functional class III or IV (Chavey et al. 2001) at screening,
    4. Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), complete left bundle branch block, high-grade AV block (e.g., bifascicular block, Mobitz type II) and third degree AV block, unless adequately controlled by pacemaker implantation,
    5. Resting QTcF ≥450 msec (male) or ≥460 msec (female) at screening or inability to determine the QTcF interval,
    6. Risk factors for Torsades de Point (TdP), including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/symptomatic bradycardia, or any of the following:
    7. Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or
    8. Concomitant medication(s) with a "Known Risk of Torsades de Point" per www.qtdrugs.org that cannot be discontinued or replaced by safe alternative medication.
  10. Previous or concurrent malignancy with the following exceptions:

    1. Adequately treated basal cell or squamous cell carcinoma (adequate wound healing is required prior to study entry)
    2. In situ carcinoma of the cervix or breast, treated curatively and without evidence of recurrence for at least 3 years prior to the study
    3. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
    4. Adequately treated carcinoma in situ without evidence of of recurrence for at least 3 years prior to the study
    5. A primary malignancy which has been completely resected and in complete remission for ≥ 3 years
  11. Pregnant or nursing (lactating) women and women who are not confirmed to be menopausal/post-menopausal. Or women who are capable of giving birth.
  12. Intolerance to the excipients of the tisagenlecleucel cell product
  13. Active or history of inflammatory disorders or autoimmune disease that required systemic steroids or immunosuppressive medications, with exception of vitiligo or resolved childhood asthma
  14. Active tuberculosis
  15. Exposure to any investigational agent(s) within 4 weeks prior to study entry
  16. Chemotherapy less than 2 weeks before leukapheresis
  17. Simultaneous radiotherapy to tisagenlecleucel infusion (radiotherapy between leukapheresis and day -6 before tisagenlecleucel infusion is permitted)
  18. Ongoing necessity for systemic corticosteroids >10mg daily prednisone equivalent. Inhaled or topical steroids and adrenal replacement steroid doses > 10 mg daily prednisone equivalent are permitted in the absence of active autoimmune disease.
  19. History of active primary immunodeficiency
  20. Major surgery (defined as opening at least one body cavity) within 4 weeks prior to study entry
  21. History of idiopathic pulmonary fibrosis, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening CT scan
  22. Patients with a history of prior treatment with anti-PD-1, anti-PD-L1, anti-PDL2, anti-CTLA-4 antibodies, other immune checkpoint inhibitors
  23. Prior treatment with any anti-CD19/anti-CD3 therapy, or any other anti-CD19 therapy.
  24. Current treatment within another therapeutic clinical trial with experimental and not approved drugs and treatment combinations
  25. Patient's lack of accountability and inability to appreciate the nature, meaning and consequences of the trial and to formulate his/her own wishes correspondingly
  26. Non-compliance, e.g. due to

    1. Drug dependency or substance abuse that would interfere with cooperation with requirements of the trial
    2. Refusal of blood products during treatment
    3. Change of residence to abroad
    4. any similar circumstances that appear to make protocol treatment or long-term follow-up impossible
  27. Patients who have a relationship of dependence or employer-employee relationship to the sponsor or the investigator
  28. Committal to an institution on judicial or official order

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04161118


Contacts
Layout table for location contacts
Contact: Peter Borchmann, Prof. Dr. med. +49 221 478 ext 88180 Tiger_Studienteam@uk-koeln.de
Contact: Anja Juehling, Dr. med. +49 221 478 ext 30949 Tiger_Studienteam@uk-koeln.de

Sponsors and Collaborators
University of Cologne
Novartis

Layout table for additonal information
Responsible Party: Prof. Dr. Peter Borchmann, Trial Chairman, University of Cologne
ClinicalTrials.gov Identifier: NCT04161118     History of Changes
Other Study ID Numbers: Uni-Koeln-3903
First Posted: November 13, 2019    Key Record Dates
Last Update Posted: November 13, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Lymphoma, Non-Hodgkin
Lymphoma, B-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases